KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Halozyme Therapeutics (HALO) Work In Process (2016 - 2025)

Historic Work In Process for Halozyme Therapeutics (HALO) over the last 16 years, with Q3 2025 value amounting to $34.8 million.

  • Halozyme Therapeutics' Work In Process rose 13404.54% to $34.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $34.8 million, marking a year-over-year increase of 13404.54%. This contributed to the annual value of $30.2 million for FY2024, which is 1133.28% down from last year.
  • Per Halozyme Therapeutics' latest filing, its Work In Process stood at $34.8 million for Q3 2025, which was up 13404.54% from $30.9 million recorded in Q2 2025.
  • Halozyme Therapeutics' Work In Process' 5-year high stood at $56.2 million during Q3 2022, with a 5-year trough of $6.3 million in Q1 2022.
  • Over the past 5 years, Halozyme Therapeutics' median Work In Process value was $34.0 million (recorded in 2023), while the average stood at $32.0 million.
  • Per our database at Business Quant, Halozyme Therapeutics' Work In Process tumbled by 6742.97% in 2022 and then surged by 33275.43% in 2023.
  • Quarter analysis of 5 years shows Halozyme Therapeutics' Work In Process stood at $17.5 million in 2021, then skyrocketed by 152.72% to $44.1 million in 2022, then dropped by 22.85% to $34.0 million in 2023, then decreased by 11.33% to $30.2 million in 2024, then rose by 15.48% to $34.8 million in 2025.
  • Its Work In Process was $34.8 million in Q3 2025, compared to $30.9 million in Q2 2025 and $36.7 million in Q1 2025.